Catalyst Event
InnoCare Pharma Ltd (9969) · Other
From Akros SCHK HK-Global Genomics Index (ASHGGENM)
5/13/2026, 12:00:00 AM
Announced that the first subject has been dosed in the Phase 1 clinical trial of ICP-054 (ZB021), a novel oral IL-17AA/AF inhibitor for autoimmune diseases. Early-stage clinical progress is estimated to have a low market impact (>1%).
Korean Translation
자가면역질환 치료를 위한 신규 경구용 IL-17AA/AF 억제제인 ICP-054(ZB021)의 1상 임상시험에서 첫 번째 시험대상자 투여를 완료함. 초기 임상 단계 진전으로 인해 1% 이상의 시장 영향이 예상됨.
Related Recent Events
JD Health International Inc (6618) · Earnings Release
Low importance estimated as no market reaction has occurred yet; Q2 2026 earnings report scheduled.
8/12/2026, 12:00:00 AM
Livzon Pharmaceutical Group Inc (1513) · Other
Ex-dividend date on June 16, 2026, for the final dividend of RMB 1.43 per 10 shares, scheduled to be paid on July 13, 2026. Low importance estimated as the dividend amount is within historical norms, scheduled.
6/16/2026, 12:00:00 AM
Grand Pharmaceutical Group Ltd (512) · Other
Ex-dividend date (2026-06-12) for the proposed 2025 final dividend of HK$0.169 per share is scheduled.
6/12/2026, 12:00:00 AM
Veracyte Inc (VCYT) · Other
Annual Meeting of Stockholders on 2026-06-10, with proposals including the election of directors and an expansion of the 2023 Equity Incentive Plan scheduled.
6/10/2026, 12:00:00 AM
Innovent Biologics Inc (1801) · Other
Innovent will present obesity pipeline data at the ADA Scientific Sessions on June 5-8, 2026; this low-impact event is scheduled
6/5/2026, 12:00:00 AM
Pacific Biosciences of California Inc (PACB) · Other
The 2026 Annual Meeting of Stockholders is scheduled for June 3, 2026, including a proposal to increase the number of shares reserved for the 2020 Equity Incentive Plan by 16,000,000. A low impact is estimated due to potential share dilution, scheduled.
6/3/2026, 12:00:00 AM